The inhibitor that can selectively block p38 will prevent producing these destructive cytokines and ultimately alleviate the onset of inflammatory disease, such as RA, inflammatory bowel disease (IBD), psoriasis, stroke, myocardial ischemia, alzheimer disease, and respiratory disease (7, 8). Here, MAPK14 is linked to rheumatoid arthritis.